Editas Medicine Inc Stock Research

Market Summary

USD8.49+0.06

Market Closed

0.71%

EDIT Stock Price

EDIT RSI Chart

EDIT Valuation

Market Cap

584.5M

Price/Earnings (Trailing)

-2.65

Price/Sales (Trailing)

29.65

Price/Free Cashflow

-3.22

EDIT Price/Sales (Trailing)

EDIT Profitability

Return on Equity

-61.12%

Return on Assets

-42.86%

Free Cashflow Yield

-31.05%

EDIT Fundamentals

EDIT Revenue

Revenue (TTM)

19.7M

Revenue Y/Y

-47.58%

Revenue Q/Q

1.35%

EDIT Earnings

Earnings (TTM)

-220.4M

Earnings Y/Y

-46.58%

Earnings Q/Q

-8.99%

Price Action

52 Week Range

7.4821.60

(Low)(High)

Last 7 days

-4.1%

Last 30 days

-15.6%

Last 90 days

-15.8%

Trailing 12 Months

-43.5%

EDIT Financial Health

Current Ratio

5.94

EDIT Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-3.21

Peers (Alternatives to Editas Medicine)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	125.3B	26.3B	-2.75%	3.76%	19.12	4.76	1.32%	11.18%
GILD	99.6B	27.3B	-8.96%	41.01%	21.68	3.65	-0.09%	-26.23%
MRNA	58.4B	19.3B	-12.76%	1.00%	6.99	3.03	4.29%	-31.47%
BIIB	38.3B	10.2B	-9.67%	32.94%	12.57	3.76	-7.36%	95.80%
MID-CAP
NBIX	9.1B	1.5B	-9.09%	3.35%	58.87	6.11	31.34%	72.43%
DNLI	3.2B	108.5M	-21.10%	-19.55%	-9.78	29.38	122.90%	-12.19%
BEAM	2.5B	60.9M	-18.47%	-36.46%	-8.76	41.55	17.51%	22.00%
BBIO	2.1B	107.9M	22.95%	67.45%	-4.29	19.27	54.84%	17.36%
SMALL-CAP
RCUS	1.2B	112.0M	-14.86%	-46.41%	-4.63	11.04	-70.76%	-603.77%
REPL	1.1B	7.0M	-22.18%	24.65%	-7.11	158.97	131.81%	-45.39%
FATE	541.9M	96.3M	-12.99%	-82.24%	-1.92	5.63	72.44%	-32.79%
NVAX	513.7M	2.0B	-39.67%	-92.01%	-0.78	0.26	72.89%	62.27%
SGMO	355.3M	111.3M	-30.55%	-58.78%	-1.85	3.19	0.54%	-7.86%
VXRT	101.4M	159.0K	-16.47%	-82.96%	-0.97	637.62	-86.46%	-64.56%
IBIO	25.1M	-	94.03%	-77.12%	-0.31	3.21	0.51%	-185.61%

Financials for Editas Medicine

* denotes actual numbers (not divided by Millions)
Income Statement (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-23.5%	20.00	26.00	32.00	29.00	26.00
Operating Expenses	6.9%	246	230	218	213	219
S&GA Expenses	2.1%	71.00	69.00	69.00	74.00	76.00
R&D Expenses	9.0%	175	161	148	139	143
Net Income	-9.6%	-220	-201	-184	-186	-192
Net Income Margin	-43.2%	-11.18*	-7.81*	-5.80*	-6.50*	-
Free Cahsflow	-3.1%	-181	-176	-170	-173	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Assets	-3.1%	514	531	581	623	677
Current Assets	-16.4%	357	427	461	497	507
Cash Equivalents	-32.8%	142	211	169	211	204
Net PPE	0.5%	16.00	15.00	16.00	17.00	17.00
Liabilities	32.1%	154	116	115	110	124
Current Liabilities	42.1%	60.00	42.00	36.00	37.00	47.00
Shareholder's Equity	-13.0%	361	415	465	513	554
Retained Earnings	-7.8%	-1,078	-1,000	-961	-908	-857
Additional Paid-In Capital	0.4%	1,442	1,436	1,430	1,423	1,412
Shares Outstanding	0.1%	69.00	69.00	69.00	69.00	68.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-4.5%	-177,349	-169,658	-162,439	-163,551	-163,803
Share Based Compensation	-7.3%	29,294	31,587	35,718	42,626	43,399
Cashflow From Investing	-3.9%	114,068	118,756	-10,132	-1,339	-54,466
Cashflow From Financing	-25.4%	1,284	1,722	4,138	20,853	282,106

Risks for EDIT

What is the probability of a big loss on EDIT?

100%

Probability that Editas Medicine stock will be more than 20% underwater in next one year

88.8%

Probability that Editas Medicine stock will be more than 30% underwater in next one year.

78.1%

Probability that Editas Medicine stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does EDIT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Editas Medicine was unfortunately bought at previous high price.

Drawdowns

Returns for EDIT

Cumulative Returns on EDIT

-17.0%

7-Year Cumulative Returns

-26.0%

5-Year Cumulative Returns

-24.2%

3-Year Cumulative Returns

What are the long-term rolling returns for EDIT?

FIve years rolling returns for Editas Medicine.

Annualized Returns

Which funds bought or sold EDIT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-03-15	B. Riley Wealth Advisors, Inc.	sold off	-100	-132,000	-	-%
2023-03-06	Rockefeller Capital Management L.P.	reduced	-9.33	-79,000	152,000	-%
2023-02-28	Voya Investment Management LLC	unchanged	-	-89,827	236,173	-%
2023-02-27	Parallax Volatility Advisers, L.P.	reduced	-96.22	-1,158,400	32,597	-%
2023-02-24	NATIXIS	new	-	23,647	23,647	-%
2023-02-21	MACQUARIE GROUP LTD	sold off	-100	-24,000	-	-%
2023-02-21	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	reduced	-99.68	-2,991	9.00	-%
2023-02-16	HARBOUR INVESTMENTS, INC.	added	5.63	-671	4,329	-%
2023-02-16	GHP Investment Advisors, Inc.	unchanged	-	-226	1,774	-%
2023-02-15	Financial Advocates Investment Management	sold off	-100	-943,000	-	-%

Latest Funds Activity

Are funds buying EDIT calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own EDIT

No. of Funds

Editas Medicine News

Schedule 13G FIlings of Editas Medicine

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	10.00%	6,873,123	SC 13G/A
Feb 03, 2023	state street corp	13.41%	9,222,236	SC 13G/A
Jan 26, 2023	blackrock inc.	10.7%	7,338,742	SC 13G/A
Jan 20, 2023	blackrock inc.	10.7%	7,338,742	SC 13G/A
Jul 11, 2022	state street corp	11.48%	7,879,890	SC 13G/A
Mar 09, 2022	vanguard group inc	10.69%	7,328,042	SC 13G/A
Feb 14, 2022	nikko asset management americas, inc.	3.91%	2,675,235	SC 13G/A
Feb 09, 2022	vanguard group inc	9.76%	6,673,897	SC 13G/A
Feb 09, 2022	ark investment management llc	6.17%	4,218,302	SC 13G/A
Feb 04, 2022	sumitomo mitsui trust holdings, inc.	3.91%	2,675,235	SC 13G/A

EDIT Fair Value

Editas Medicine fair value in different scenarios

The table shows the Fair Value estimates for Editas Medicine for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	1.28 -84.92%	1.31 -84.57%	1.40 -83.51%	1.55 -81.74%	1.88 -77.86%
Current Inflation	1.28 -84.92%	1.31 -84.57%	1.38 -83.75%	1.52 -82.10%	1.81 -78.68%
Very High Inflation	1.27 -85.04%	1.30 -84.69%	1.37 -83.86%	1.48 -82.57%	1.72 -79.74%

Historical Editas Medicine Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Editas Medicine

View All Filings

Date Filed	Form Type	Document
Mar 14, 2023	8-K	Current Report
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Mar 06, 2023	4	Insider Trading
Feb 22, 2023	10-K	Annual Report
Feb 22, 2023	8-K	Current Report
Feb 22, 2023	S-8	Employee Benefits Plan
Feb 15, 2023	4	Insider Trading
Feb 15, 2023	4	Insider Trading

Latest Insider Trading transactions for EDIT

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-03	Eaton Bruce	sold	-897	8.89	-101	evp, cbo and cto
2023-03-03	ROBERTSON MICHELLE	sold	-1,635	8.89	-184	evp, chief financial officer
2023-03-02	Mei Baisong	acquired	-	-	18,000	svp, chief medical officer
2023-03-02	O'Neill Gilmore Neil	acquired	-	-	50,000	ceo
2023-03-02	ROBERTSON MICHELLE	acquired	-	-	31,500	evp, chief financial officer
2023-03-02	Eaton Bruce	acquired	-	-	16,700	evp, cbo and cto
2023-02-13	ROBERTSON MICHELLE	sold	-41,435	9.6653	-4,287	evp, chief financial officer
2023-02-13	Eaton Bruce	sold	-31,963	9.6653	-3,307	evp, cbo and cto
2023-02-13	Shearman Mark S	sold	-26,966	9.6653	-2,790	evp, chief scientific officer
2023-02-07	Eaton Bruce	sold	-3,840	11.1	-346	evp, cbo and cto

About Editas Medicine

James C. Mullen

www.editasmedicine.com

260

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

EDIT Income Statement

2022-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Operations
Collaboration and other research and development revenues	$ 19,712	$ 25,544	$ 90,732
Revenue type	us-gaap:ServiceMember	us-gaap:ServiceMember	us-gaap:ServiceMember
Operating expenses:
Research and development	$ 174,958	$ 142,507	$ 157,996
General and administrative	70,704	76,183	67,576
Total operating expenses	245,662	218,690	225,572
Operating loss	(225,950)	(193,146)	(134,840)
Other income, net:
Other income (expense), net	1,293	(1,698)	16,259
Interest income, net	4,225	2,342	2,605
Total other income, net	5,518	644	18,864
Net loss	(220,432)	(192,502)	(115,976)
Net loss, basic	(220,432)	(192,502)	(115,976)
Net loss, diluted	$ (220,432)	$ (192,502)	$ (115,976)
Net loss per share, basic (in dollars per share)	$ (3.21)	$ (2.85)	$ (1.98)
Net loss per share, diluted (in dollars per share)	$ (3.21)	$ (2.85)	$ (1.98)
Weighted-average common shares outstanding, basic (in shares)	68,664,822	67,619,388	58,609,389
Weighted-average common shares outstanding, diluted (in shares)	68,664,822	67,619,388	58,609,389

EDIT Balance Sheet

2022-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 141,522	$ 203,519
Marketable securities	202,752	296,326
Accounts receivable	5,145	267
Prepaid expenses and other current assets	7,335	7,198
Total current assets	356,754	507,310
Marketable securities	93,097	120,071
Property and equipment, net	15,569	17,118
Right-of-use assets	43,648	26,173
Restricted cash and other non-current assets	5,253	6,811
Total assets	514,321	677,483
Current liabilities:
Accounts payable	9,511	5,050
Accrued expenses	31,296	20,192
Deferred revenue, current	8,221	11,333
Operating lease liabilities	11,082	10,309
Total current liabilities	60,110	46,884
Operating lease liabilities, net of current portion	32,864	16,069
Deferred revenue, net of current portion	60,667	60,888
Total liabilities	153,641	123,841
Stockholders' equity
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 68,847,382 and 68,489,257 shares issued, and 68,847,382 and 68,435,257 shares outstanding at December 31, 2022 and December 31, 2021, respectively	7	7
Additional paid-in capital	1,442,405	1,411,827
Accumulated other comprehensive loss	(3,601)	(493)
Accumulated deficit	(1,078,131)	(857,699)
Total stockholders' equity	360,680	553,642
Total liabilities and stockholders' equity	$ 514,321	$ 677,483